KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash & Equivalents: 2010-2024

Historic Cash & Equivalents for TherapeuticsMD (TXMD) over the last 15 years, with Dec 2024 value amounting to $5.1 million.

  • TherapeuticsMD's Cash & Equivalents rose 40.97% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year increase of 40.97%. This contributed to the annual value of $5.1 million for FY2024, which is 16.92% up from last year.
  • As of FY2024, TherapeuticsMD's Cash & Equivalents stood at $5.1 million, which was up 16.92% from $4.3 million recorded in FY2023.
  • Over the past 5 years, TherapeuticsMD's Cash & Equivalents peaked at $80.5 million during FY2020, and registered a low of $4.3 million during FY2023.
  • Over the past 3 years, TherapeuticsMD's median Cash & Equivalents value was $5.1 million (recorded in 2024), while the average stood at $19.6 million.
  • In the last 5 years, TherapeuticsMD's Cash & Equivalents plummeted by 91.23% in 2023 and then increased by 16.92% in 2024.
  • TherapeuticsMD's Cash & Equivalents (Yearly) stood at $80.5 million in 2020, then dropped by 19.36% to $64.9 million in 2021, then fell by 24.02% to $49.3 million in 2022, then plummeted by 91.23% to $4.3 million in 2023, then rose by 16.92% to $5.1 million in 2024.